A Study of Lorigerlimab in Participants With Advanced Solid Tumors
A phase 2 trial of Lorigerlimab in ovarian cancer and endometrial cancer, run by MacroGenics, now recruiting.
Overview
A Study of Lorigerlimab in Participants With Advanced Solid Tumors is a phase 2 interventional study registered as NCT06730347 by MacroGenics, with 80 participants planned, started 2025-05-01 and due to reach its primary completion in 2027-07. Interventions recorded: Lorigerlimab. Conditions listed: Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Clear Cell Adenocarcinoma of Ovary. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- PersonRobert S. Mannel
Shares Endometrial cancer, Ovarian cancer.
- PersonKaren H. Lu
Shares Endometrial cancer, Ovarian cancer.
- PersonMatthew A. Powell
Shares Endometrial cancer, Ovarian cancer.
- TrialA Study of DM002 in Patients With Advanced Solid Tumors
Shares Endometrial cancer, Ovarian cancer.
- TrialA Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
Shares Endometrial cancer, Ovarian cancer.
- PersonJalid Sehouli
Shares Endometrial cancer, Ovarian cancer.
- TrialHS-20089 in Patients With Ovarian Cancer and Endometrial Cancer
Shares Endometrial cancer, Ovarian cancer.
- PersonSébastien Armanet
Shares Endometrial cancer, Ovarian cancer.